•  
  •  
  •  
  •  

2025-12-17 03:52:16

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Tamilnadu Petroproducts Ltd receives TNPCB nod for expanded capacity of Linear Alkyl Benzene plant
  • S&P Upgrades IIFL Finance's Outlook to 'Positive' On Recovering Market Share in Gold Loans, 'B+/B' Ratings Affirmed
  • Trishakti Industries Ltd secures order from Afcons Infrastructure Ltd
  • Persistent and DigitalOcean announce strategic partnership to advance accessible, scalable and secure AI
  • ITCONS E-Solutions Ltd bags new contract

Keywords Selected:  DrLalPathLabs

Stock Report

  • Dr. Lal PathLabs Strengthens Autoimmune Diagnosis with India's First Comprehensive Complement Lab
  • Dr Lal PathLabs Limited recommends 1:1 bonus issue
  • Dr Lal PathLabs Limited declares 2nd interim dividend of Rs. 7
  • Dr Lal Path Labs Ltd reports Rs. 150.6 crores consolidated profit in Q2 FY26
  • Dr Lal PathLabs Limited approves acquisition of property in New Delhi
  • Dr. Lal PathLabs Pioneers AI Integration in Cancer Diagnosis in India
  • Dr. Lal PathLabs strengthens its genomics capabilities with Illumina's NovaSeq X Series
  • Dr. Lal PathLabs Limited recommends final dividend of Rs. 6
  • Dr. Lal Path Labs Ltd Q4FY25 consolidated PAT jumps to Rs. 154.8 crores
  • Dr. Lal PathLabs becomes South Asia's First Diagnostic Chain to Launch Advanced Test for Amyloidosis
  • Antara, partners with leading diagnostics player Dr. Lal PathLabs to strengthen its geriatric care services
  • Dr. Lal PathLabs Ltd Q2FY25 consolidated net profit increases to Rs. 129.2 crores
  • Dr. Lal PathLabs Limited recommends final dividend of Rs. 6
  • Dr. Lal PathLabs Ltd posts Rs. 84.5 crores consolidated PAT in Q4 FY24
  • Dr Lal Path Labs Ltd Q3FY24 consolidated net profit lower at Rs. 81.3 crores
  • Dr Lal Path Labs Ltd consolidated Q2 FY24 PAT jumps to Rs. 109.3 crores
  • Dr. Lal PathLabs Ltd approves interim dividend of Rs. 6
  • Dr. Lal Path Labs Ltd posts jump in Q1FY24 consolidated PAT to Rs. 82.6 crores
  • Dr. Lal PathLabs Ltd recommends final dividend of Rs. 6
  • Dr. Lal Path Labs Ltd reports QoQ increase in Q4FY23 consolidated net profit to Rs. 56.7 crores
  • Dr. Lal PathLabs Selects Kyndryl for Seamless Cloud Services Management
  • Dr. Lal Path Labs Ltd posts consolidated PAT of Rs. 52.9 crores in Q3FY23
  • Dr Lal Path Labs Ltd reports Rs. 71.7 crores consolidated profit in Q2FY23
  • Dr. Lal PathLabs Ltd declares interim dividend of Rs. 6

Latest Post

  • Tamilnadu Petroproducts Ltd receives TNPCB nod for expanded capacity of Linear Alkyl Benzene plant
  • S&P Upgrades IIFL Finance's Outlook to 'Positive' On Recovering Market Share in Gold Loans, 'B+/B' Ratings Affirmed
  • Trishakti Industries Ltd secures order from Afcons Infrastructure Ltd
  • Persistent and DigitalOcean announce strategic partnership to advance accessible, scalable and secure AI
  • ITCONS E-Solutions Ltd bags new contract


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024